The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary
CAP (College of American Pathologists). 2007. HER2 and you: Guidelines provided by CAPand ASCO. Northfield, IL: CAP.
Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc RIIIa gene. Blood 99(3):754–758.
Di Nicolantonio, F., M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, and A. Bardelli. 2008. Wild-type BRAC is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Journal of Clinical Oncology 26(35):5705–5712.
EGAPP Working Group (Evaluation of Genomic Applications in Practice and Prevention Working Group). 2009a. Recommendations from the EGAPP Working Group: Can tumor gene expression profiling improve outcomes in patients with breast cancer? Genetics in Medicine 11(1):66–73.
EGAPP Working Group. 2009b. Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genetics in Medicine 11(1):15–20.
FDA (Food and Drug Administration). 1997. Medical devices; classification/reclassification; restricted devices; analyte specific reagents—FDA. Final Rule. Federal Register 62(225):62243–62260.